Chairman Michael J. Farrell - 07 Nov 2024 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Issuer symbol
RMD
Transactions as of
07 Nov 2024
Net transactions value
-$4,584,243
Form type
4
Filing time
12 Nov 2024, 17:37:30 UTC
Previous filing
09 Oct 2024
Next filing
27 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $1,247,761 +14,683 +3.2% $84.98 478,937 07 Nov 2024 Direct F1, F2
transaction RMD ResMed Common Stock Sale $3,615,821 -14,683 -3.1% $246.26 464,254 07 Nov 2024 Direct F3, F4
transaction RMD ResMed Common Stock Tax liability $782,725 -3,101 -0.67% $252.38 461,152 11 Nov 2024 Direct F5
transaction RMD ResMed Common Stock Tax liability $562,016 -2,227 -0.48% $252.38 458,925 11 Nov 2024 Direct F6
transaction RMD ResMed Common Stock Tax liability $871,443 -3,453 -0.75% $252.38 455,472 11 Nov 2024 Direct F7
holding RMD ResMed Common Stock 4,090 07 Nov 2024 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -14,683 -100% $0.000000 0 07 Nov 2024 ResMed Common Stock 14,683 $84.98 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.
F2 Includes 84.129 shares of ResMed stock purchased on October 31, 2024, through the ResMed Employee Stock Purchase Plan.
F3 The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.
F4 This transaction was executed in multiple trades at prices ranging from $244.74 - $248.38 The price reported above reflects the weighted average sale price.
F5 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021.
F6 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022.
F7 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023.
F8 The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.
F9 Represents date options first become exercisable. Options vest 1/3 per year.